Syndax Pharmaceuticals, Inc. · Healthcare · Biotechnology
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$21.73
+$1.06 (+5.10%) 4:00 PM ET
After hours$21.50
−$0.23 (−1.04%) 6:49 PM ET
Prev closePrevC$20.67
OpenOpen$20.06
Day highHigh$21.73
Day lowLow$19.43
VolumeVol2,177,016
Avg volAvgVol1,201,529
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$1.89B
P/E ratio
-6.60
FY Revenue
$172.60M
EPS
-3.29
Gross Margin
95.96%
Sector
Healthcare
AI report sections
BULLISH
SNDX
Syndax Pharmaceuticals, Inc.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
+137% (Above avg)
Vol/Avg: 2.37×
RSI
50.33(Neutral)
Neutral (40–60)
0255075100
MACD momentum
Intraday
+0.00 (Strong)
MACD: 0.11 Signal: 0.11
Short-Term
-0.03 (Weak)
MACD: -0.09 Signal: -0.06
Long-Term
-0.07 (Weak)
MACD: 0.07 Signal: 0.13
Intraday trend score
81.50
LOW54.00HIGH81.50
Latest news
SNDX•12 articles•Positive: 9Neutral: 1Negative: 1
PositiveGlobeNewswire Inc.• Na
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
Syndax Pharmaceuticals and the World Orphan Drug Alliance announced a collaboration to expand access to Revuforj (revumenib), a first-in-class menin inhibitor, through a Managed Access Program in regions including parts of Eurasia, Central and Southeast Europe, Israel, the Middle East, Turkey, Latin America, and Africa where the drug is not yet commercially available.
The announcement demonstrates strategic expansion of Revuforj's market reach beyond the U.S., enabling access in multiple regions and supporting long-term goals to establish the drug as a standard of care globally. This partnership with WODA enhances the company's mission and market penetration without requiring independent infrastructure development.
PositiveGlobeNewswire Inc.• Michael A. Metzger
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
Syndax Pharmaceuticals' CEO will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference, discussing the company's innovative cancer therapies and pipeline developments.
Company is showcasing its innovative cancer therapies, highlighting FDA-approved drugs Revuforj and Niktimvo, and actively conducting clinical trials, indicating growth and strategic development
Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
The FDA approved Revuforj (revumenib) for treating relapsed or refractory acute myeloid leukemia with NPM1 mutation in adult and pediatric patients, marking the first and only therapy approved for multiple acute leukemia subtypes.
Received FDA approval for a new therapeutic indication, expanding the market potential of their drug Revuforj and demonstrating successful clinical development
Menin Inhibitors Drug Market Report 2025: Price, Sales & Clinical Trials Insights 2024-2028 - Kura Oncology & Kyowa Kirin Progress with New Drug Applications
Market report highlights emerging menin inhibitor drugs targeting high-risk acute leukemias, with over 15 drugs in clinical trials and potential market opportunity exceeding $400 million by 2028.
Achieved first approval of revumenib for KMT2A-rearranged AML and seeking additional indication
NeutralGlobeNewswire Inc.• Sharon Klahre
Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025
Syndax Pharmaceuticals will report its Q2 2025 financial results and host a conference call on August 4, 2025, providing an update on its innovative cancer therapies and ongoing clinical trials.
The article is a standard financial results announcement without significant positive or negative indicators, presenting routine corporate communication about upcoming earnings report
PositiveGlobeNewswire Inc.• N/A
Syndax Announces Participation in June Investor Conferences
Syndax Pharmaceuticals announced that it will present data on its cancer therapies Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) at the upcoming EHA 2025 conference.
The article highlights Syndax's upcoming data presentations at a major conference, showcasing its cancer therapy pipeline, which suggests the company is making progress in its research and development efforts.
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Syndax Pharmaceuticals reported strong initial sales of its cancer drug Revuforj and launched its chronic GVHD drug Niktimvo in the U.S. The company expects to submit a supplemental NDA for Revuforj in relapsed/refractory mNPM1 AML in 2Q25 and has a robust development strategy underway for both drugs.
The article highlights Syndax's strong initial sales of Revuforj, the upcoming sNDA filing for Revuforj in mNPM1 AML, and the robust development strategy for both Revuforj and Niktimvo, indicating the company's progress and potential.
PositiveGlobeNewswire Inc.• N/A
Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025
Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company, will report its fourth quarter and full year 2024 financial results and provide a business update on March 3, 2025.
The article announces that Syndax Pharmaceuticals will report its financial results and provide a business update, indicating the company's ongoing operations and progress.
NegativeGlobeNewswire Inc.• N/A
Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm
Kuehn Law, a shareholder litigation law firm, is investigating potential self-dealing by officers and directors of Syndax Pharmaceuticals, Inc. (SNDX). Shareholders may be entitled to damages and corporate governance reforms.
The article indicates that Kuehn Law is investigating potential breaches of fiduciary duties by Syndax Pharmaceuticals' officers and directors, which suggests potential wrongdoing or mismanagement within the company.
PositiveGlobeNewswire Inc.• Delveinsight
Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
The pulmonary fibrosis market is driven by the increasing prevalence of the disease, especially idiopathic pulmonary fibrosis, among the aging population. Innovations in drug development and diagnostics, favorable reimbursement policies, and greater awareness are fueling market growth. The pipeline appears robust with over 110 active players working on 120+ pipeline drugs.
Syndax Pharmaceuticals is one of the key companies actively working on the pulmonary fibrosis pipeline, indicating a strong focus on addressing the unmet needs in this therapeutic area.
PositiveGlobeNewswire Inc.• Delveinsight
Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight
The graft versus host disease market is experiencing significant growth, driven by the adoption of branded therapies, a strong pipeline with the anticipated launch of over 10 new drugs, and increased awareness of GvHD management. Innovative treatments and ongoing research are expected to further expand market opportunities.
EQTAKCSLLYSNDXGraft versus Host DiseaseMarket GrowthBranded TherapiesPipeline
Sentiment note
Syndax Pharmaceutical is developing the GvHD therapy SNDX-6352 (axatilimab), which is expected to contribute to the growth of the GvHD market.
UnknownZacks Investment Research• Zacks Equity Research
Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.
NVSLLYINCYSNDX
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
